Cargando…
LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
BACKGROUND: LMD has a dismal prognosis with median survivals of 8–10 weeks. Recently the first phase 2 trial of PD-1 inhibitor monotherapy in solid tumor LMD showed median overall survival (OS) 3.6 months. We aimed to determine the safety/efficacy of avelumab with WBRT in patients with LMD from soli...
Autores principales: | Pina, Yolanda, Chen, Ann, Arrington, John, Macaulay, Robert, Tran, Nam, Liu, James, Mokhtari, Sepideh, Li, Jiannong, Law, Vincent, Sahebjam, Solmaz, Ahmed, Kamran, Creelan, Ben, Gray, Jhanelle, Khushalani, Nikhil, Smalley, Inna, Smalley, Keiran, Vogelbaum, Michael, Yu, Michael, Forsyth, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351314/ http://dx.doi.org/10.1093/noajnl/vdab071.030 |
Ejemplares similares
-
SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR ANALYSES WITH SINGLE CELL RNA SEQUENCING
por: Pina, Yolanda, et al.
Publicado: (2023) -
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
por: Khaled, Mariam Lotfy, et al.
Publicado: (2023) -
Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review
por: Wallace, Gerald, et al.
Publicado: (2023) -
Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
por: Ferguson, Sherise D., et al.
Publicado: (2022) -
LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma
por: Lowe, Stephen, et al.
Publicado: (2021)